A multi-ingredient NMN stack with BHB and ginsenosides was tied to a roughly 4-year drop in the DNAm PhenoAge epigenetic clock. The catch is that the figure came from an uncontrolled pilot of just eight people, and the authors say it does not establish age reversal. The main 42-day trial had about 10 people per arm, was open-label, and found no significant between-group improvements in cardiopulmonary or cognitive outcomes. This article breaks down what the study did show, the conflict-of-interest details, and how to read clock claims on supplement labels.
This page is available in